statistiche ricercatore

Nazione	#
IT - Italia	9.137
US - Stati Uniti d'America	557
SG - Singapore	170
CN - Cina	120
SE - Svezia	63
VN - Vietnam	57
BR - Brasile	41
DE - Germania	31
FR - Francia	27
IN - India	26
GB - Regno Unito	19
HK - Hong Kong	19
NL - Olanda	19
CA - Canada	14
FI - Finlandia	11
BD - Bangladesh	9
PL - Polonia	9
AR - Argentina	8
AT - Austria	7
KR - Corea	7
IQ - Iraq	6
IR - Iran	6
TR - Turchia	6
AE - Emirati Arabi Uniti	5
EC - Ecuador	4
ES - Italia	4
GR - Grecia	4
ID - Indonesia	4
IL - Israele	4
JP - Giappone	4
PH - Filippine	4
PK - Pakistan	4
TH - Thailandia	4
VE - Venezuela	4
AU - Australia	3
CO - Colombia	3
RU - Federazione Russa	3
SA - Arabia Saudita	3
UZ - Uzbekistan	3
ZA - Sudafrica	3
BH - Bahrain	2
CL - Cile	2
LT - Lituania	2
MA - Marocco	2
MX - Messico	2
NG - Nigeria	2
BB - Barbados	1
BO - Bolivia	1
CR - Costa Rica	1
EG - Egitto	1
IE - Irlanda	1
KE - Kenya	1
LU - Lussemburgo	1
MN - Mongolia	1
MO - Macao, regione amministrativa speciale della Cina	1
NO - Norvegia	1
OM - Oman	1
PE - Perù	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	10.460

Nome	#
Molecular-biology-driven treatment for metastatic colorectal cancer	2.771
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment	1.357
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors	1.074
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?	934
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment	868
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression	785
Uncovering key targets of success for immunotherapy in pancreatic cancer	720
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus	676
BRCA-mutant pancreatic ductal adenocarcinoma	618
Immune Checkpoint Inhibitors in the Treatment of HCC	590
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line	100
Totale	10.493

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	172	0	0	0	0	0	0	0	0	0	70	49	53
2021/2022	900	53	48	3	25	40	82	47	101	51	91	179	180
2022/2023	2.128	240	297	200	148	169	213	99	97	151	274	157	83
2023/2024	1.655	69	49	69	92	138	296	300	135	78	82	173	174
2024/2025	3.803	1.147	1.264	316	349	176	239	166	20	24	38	21	43
2025/2026	1.048	106	70	82	94	80	88	254	121	77	76	0	0
Totale													10.493

UNICA IRIS Institutional Research Information System